CYP19A1 and polycystic ovary syndrome: During the past decade, letrozole (aromatase inhibitor approved by FDA for the treatment of postmenopausal women with breast cancer) has been successfully used for induction of ovulation in anovulatory patients with polycystic ovary syndrome (PCOS) and for augmentation of ovulation in ovulatory women [6,9].